Sarina Berger Elmariah, MD, PhD, MPH, discusses 3-year nemolizumab data in early responders and what IL-31 blockade means for itch and atopic dermatitis.

At Fall Clinical 2026, Aaron S. Farberg, MD, shares how gene expression testing guides melanoma and atopic dermatitis care and what Ameluz PDT adds.

A roundup of updates spanning PsO, atopic dermatitis, alopecia areata, vitiligo, palmoplantar pustulosis, cutaneous sarcoidosis, and discoid lupus.

Catch up on HCPLive’s second-half Fall Clinical 2026 coverage, from HS underdiagnosis in men and long-term acne data to advanced cutaneous SCC care.

In ADtouch, lebrikizumab improved clearance, itch, and pain in hand and foot atopic dermatitis. Shawn Kwatra, MD, discusses what the data mean.

A roundup of highlights from EADV Congress 2026 in Vienna, spanning dupilumab real-world data, pipeline biologics, and a first-in-class oral agent.

US claims data from Fall Clinical 2026 suggest hidradenitis suppurativa symptoms occur at similar rates in both sexes, hinting at underdiagnosis in males.

Jennifer Hsiao, MD, discusses HS treatment expectations, biologic selection, oral JAK inhibitors, and comorbidity screening.